Paolo Morgese | Director, Market Access And Member Relations
Alliance for Regenerative Medicine

Paolo Morgese, Director, Market Access And Member Relations, Alliance for Regenerative Medicine

Paolo is a healthcare investment and market access professional with more than 15 years of experience in both assessing and supporting access to innovative healthcare technologies. Since 2017, Paolo is EU Director Market Access and Members Relations at the Alliance for Regenerative Medicine (ARM) Between 2012 and 2017 he worked at Deerfield Management, a healthcare investment company, where he was Director of EU Research and Market Access. Prior to that, he worked at Merck Serono for five years, at Kyphon (then Medtronic), and also spent 4 years with the Italian HTA Agency Agenas. Paolo’s interests and expertise are centered around healthcare technology value assessment and maximization, with a particular interest in the early stages of product development. He is an engaged stakeholder in EU and international policy debates around access to cell and gene therapies, health technology assessment convergence, early dialogue activities and value-based pricing/contracting. In addition to his role at ARM, Paolo is also VP Market Access at Alira Health, an healthcare consulting firm.

Appearances:



Conference Day 1 - Tuesday 31st March 2020 @ 15:40

Getting ready: ARM and access to ATMPs in Europe

  • Access status and expectations for the years to come
  • Challenges and solutions identified by stakeholders
  • RWE infrastructure and new payment models

Conference Day 1 - Tuesday 31st March 2020 @ 17:00

Panel discussion: Finding the right framework for reimbursement and market access for cell and gene therapies

  • Updates on current EU pricing and contracts for Kymriah, Yescarta and Luxturna
  • Structured reimbursement system for hospital-based treatments in Europe: how is this working so far in 2020?
  • How should be looking at transformative therapy pricing in the next 5 years?
  • What is possible for statutory health insurance framework in the EU?
last published: 04/Jun/20 08:25 GMT

back to speakers